Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2017 /
The REACT trial: Celecoxib vs placebo for primary breast cancer

5th - 9th Dec 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 09.12.17
Views: 1077

Prof Charles Coombes - Imperial College School of Medicine, London, UK

Prof Charles Coombes speaks with ecancer at SABCS 2017 to discuss the REACT trial of celecoxib vs placebo for primary breast cancer.

He discusses the mixed history of COX2 in breast cancer and its interactions with prostaglandin, which come alongside drug repurposing of aspirin which acts through COX 1 and 2.

The trial was broadly negative, and Prof Coombes considers if there might be a subtle signals for COX activity that might inform patient selection and treatments in the future.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation